The standard course of 12-month dual antiplatelet therapy (DAPT) with aspirin plus a potent
P2Y12 inhibitor (ie, prasugrel or ticagrelor) is established to be an effective strategy in …

Dual antiplatelet therapy (DAPT) is a cornerstone of the management of patients with acute
coronary syndrome (ACS) who were treated with percutaneous coronary intervention (PCI) …

Antiplatelet therapy is essential to reduce athero-thrombotic events in patients undergoing
percutaneous coronary intervention (PCI), but this strategy is inevitably associated with an …

Acute coronary syndromes (ACS) are most commonly, but not exclusively, precipitated by
atherosclerotic plaque rupture or erosion, leading to a platelet-driven thrombotic response …

“Everything should be madeas simple as possible, but not simpler.” The words of Albert
Einstein as paraphrased by Roger Sessions capture the problem clinicians currently face …

Dual antiplatelet therapy (DAPT)(aspirin combined with a P2Y12 blocker) is the cornerstone
of the treatment of patients who have undergone percutaneous coronary intervention (PCI) …

Dual antiplatelet therapy (DAPT) remains the therapeutic cornerstone in post-percutaneous
coronary intervention (PCI) patients; however, its duration has not been conclusively …

In patients undergoing percutaneous coronary intervention (PCI) with stent implantation,
dual antiplatelet therapy (DAPT), defined as the combination of aspirin and a P2Y 12 …

A mandatory period of dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y12
inhibitor is recommended after percutaneous coronary intervention (PCI) and/or acute …

Heart Association guidelines on duration of dualantiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) give a class I …